Compare Amplitude Inc (AMPL) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Crispr Therapeutics AG — how do they compare? Amplitude Inc trades at $12.78 (market cap $1.59B), while Crispr Therapeutics AG trades at $53.9 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 3.3× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| AMPL | CRSP | |
|---|---|---|
Market Cap | $1.59B | $5.23B |
Sector | Technology | Health |
52-Week High | $12.69 | $76.78 |
52-Week Low | $5.61 | $44.34 |
Enterprise Value | $1.45B | $3.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
